Gordian Biotechnology
Gordian Biotechnology is a private South San Francisco biotech operating a proprietary in vivo mosaic screening and AI-driven (Pythia) drug discovery platform to identify therapies for age-related diseases, serving large pharmaceutical partners (e.g., Pfizer) via non-exclusive research collaborations while building its own cardio-renal-metabolic pipeline.
- Company typePrivate
- Founded2018
- HeadquartersSouth San Francisco, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Gordian Biotechnology does
Gordian Biotechnology is a private, venture-backed drug discovery company headquartered in South San Francisco that operates a proprietary in vivo discovery platform targeting therapies for complex age-related diseases. The company's stack is organized in three integrated phases: Patient Avatars (naturally diseased or large-animal models that closely represent human disease), Mosaic Screening (pooled in vivo delivery of hundreds of gene therapies simultaneously within a single diseased animal, with barcoded readouts), and Pythia (an AI/ML layer that links single-cell transcriptomics to clinical outcomes to predict therapeutic efficacy). The platform spans multiple tissues — heart, lung, liver, joint, kidney, and adipose — and modalities including small molecules, antibodies, and gene therapies, and has been applied across osteoarthritis, MASH, HFpEF, pulmonary fibrosis, obesity, and chronic kidney disease.
Gordian pursues a dual business model: non-exclusive research collaborations with large pharmaceutical companies for target discovery, and an internal pipeline it intends to advance into the clinic. Its first named pharma partner is Pfizer, with whom it announced a non-exclusive obesity target-discovery collaboration in January 2026, and the company has stated it will continue to layer on additional cardio-renal-metabolic pharma partnerships. Revenue from internal pipeline assets is pre-commercial and not yet disclosed; collaboration economics are not publicly stated. The company was founded in October 2018 by CEO Francisco LePort (PhD in physics, formerly CSO/AI lead at Tachyus) and CSO Martin Borch Jensen (aging biology, formerly at the Buck Institute and National Institute on Aging), and had grown to approximately 30 employees by April 2024. Investors include The Longevity Fund (seed lead), Founders Fund, Fifty Years, Gigafund, Horizon Ventures, Arctica, Athos KG, K5 Global, and Prime Movers Lab, with a scientific and strategic bench that includes Jeff Dean (Google), Thomas Ebeling (ex-Novartis CEO), and Edward Lanphier (Sangamo founder/CEO), alongside named clinical advisors across HFpEF, IPF, liver, and OA.
Gordian Biotechnology firmographics
Firmographics- Name
- Gordian Biotechnology
- Legal name
- Gordian Biotechnology
- Website
- https://gordian.bio
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Gordian Biotechnology is a private South San Francisco biotech operating a proprietary in vivo mosaic screening and AI-driven (Pythia) drug discovery platform to identify therapies for age-related diseases, serving large pharmaceutical partners (e.g., Pfizer) via non-exclusive research collaborations while building its own cardio-renal-metabolic pipeline.
- Ownership category
- akta.pro rank
Gordian Biotechnology industry classification
Industry- Product category
- Drug Discovery Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK)
- akta.pro secondary industries
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where Gordian Biotechnology is headquartered
LocationHeadquarters
- HQ city
- South San Francisco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Gordian Biotechnology business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Research Collaborations with Pharma: Non-exclusive research collaborations with pharmaceutical companies to apply Gordian's in vivo screening platform for therapeutic target discovery. The Pfizer collaboration focuses on obesity target discovery. Gordian retains ability to advance partnerships across obesity and other cardio-renal-metabolic indications.
- Internal Drug Development: Building a vertically integrated pharmaceutical company developing therapeutics for age-related disorders through clinical trials. Pipeline includes osteoarthritis (OA), metabolic dysfunction-associated steatohepatitis (MASH), heart failure with preserved ejection fraction (HFpEF), pulmonary fibrosis (PF), obesity, and chronic kidney disease (CKD).
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Gordian Biotechnology product offering
Product offeringCore offering
Gordian Biotechnology operates a proprietary in vivo drug discovery platform that screens hundreds of therapeutic targets simultaneously in living animal models representative of human disease. The platform combines Patient Avatars (representative animal models, often naturally diseased), Mosaic Screening (pooled gene therapy delivery with barcoded cells), and Pythia (AI transcriptomics analysis) to identify drug targets for complex age-related diseases. Gordian monetizes this through non-exclusive research collaborations with large pharmaceutical companies (e.g., Pfizer for obesity) and internal development of its own therapeutic pipeline targeting osteoarthritis, MASH, HFpEF, pulmonary fibrosis, obesity, and chronic kidney disease.
Product overview
Gordian Biotechnology offers a unified proprietary in vivo drug discovery platform consisting of three integrated modules: Patient Avatars (Phase I) provides representative animal models that naturally represent human disease; Mosaic Screening (Phase II) enables pooled testing of hundreds of therapies simultaneously in single living animals; and Pythia (Phase III) uses AI to analyze transcriptomics data and predict clinical trial outcomes. The platform is focused on cardio-renal-metabolic indications including osteoarthritis, obesity, heart failure (HFpEF), chronic kidney disease, and pulmonary fibrosis.
Differentiator
Problem solved
Functional benefit
Brands
- Patient Avatars: Animal models that most closely represent human patients with target indications and have often acquired the disease naturally. Used as Phase I of Gordian's three-phase platform.
- Mosaic Screening
- Pythia
Products and services
- Gordian Platform Proprietary in vivo drug discovery platform that identifies therapeutic targets and therapies for complex age-related diseases by screening hundreds of gene therapies simultaneously in living animal models that closely represent human patients. Delivered to pharmaceutical partners through non-exclusive research collaborations. Pipeline targets include osteoarthritis, obesity, MASH, heart failure with preserved ejection fraction (HFpEF), pulmonary fibrosis, and chronic kidney disease.
Quantifiable outcome
- 80% predictive power for clinical outcomes demonstrated in osteoarthritis screens
- +3 more outcomes
Companies that use Gordian Biotechnology
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
Gordian Biotechnology technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature4 records
Gordian Biotechnology partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- PfizercoreGordian announced a non-exclusive research collaboration with Pfizer to apply Gordian's in vivo mosaic screening platform toward discovering therapeutic targets for obesity. The collaboration involves screening hundreds of gene targets directly within visceral adipose tissue. The platform enables in vivo transcriptional readouts for multiple targets simultaneously, providing insights into disease-relevant cell states and physiological mechanisms that cannot be replicated in traditional ex vivo or in vitro models. The agreement allows Gordian to continue advancing partnerships across obesity and other cardio-renal-metabolic indications.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Gordian Biotechnology competitors and assessment
Company assessmentDirect peers
- Recursion Pharmaceuticals: Recursion operates a high-throughput biology + AI platform for drug discovery across multiple indications. Both companies sit at the intersection of large-scale experimental biology, single-cell readouts, and ML-driven target selection, making Recursion the closest public-market comparable.
- Insitro: Insitro combines machine learning with induced pluripotent stem cell-derived disease models and pharma partnerships to discover therapeutics. Both companies couple high-throughput experimental biology with ML-based target identification to serve pharma partners and internal pipeline programs.
- Schrödinger: Schrödinger provides computational and AI-enabled drug discovery platforms and engages pharma on collaborative discovery deals. Gordian is the in vivo counterpart to Schrödinger's in silico screening stack, both monetizing through platform partnerships with large pharma.
- Valo Health: Valo Health built an AI-driven, data-centric drug discovery platform and partners with pharma across multiple therapeutic areas. Like Gordian, Valo combines proprietary data generation with ML to improve target validation and clinical translation.
- Isomorphic Labs: Alphabet-backed Isomorphic Labs applies AI to drug discovery and discovery partnerships with major pharma. It overlaps with Gordian's ML-driven discovery thesis and its strategy of serving large pharma partners through platform collaborations.
Emerging players
- BPGbio: BPGbio combines biology-first and AI approaches to identify novel targets and therapies across oncology and rare disease. It shares Gordian's thesis that integrated experimental + computational platforms outperform conventional discovery workflows.
- BioAge Labs: BioAge Labs is a clinical-stage biotech developing therapies for age-related metabolic diseases. The therapeutic-area focus on aging biology and cardiometabolic disease, plus platform-derived pipeline, makes it a credible thematic peer to Gordian's age-related disease programs.
Broad incumbents
- Ginkgo Bioworks: Ginkgo Bioworks operates a broad cell-engineering and high-throughput biology platform serving industrial and pharma customers. While not directly in drug discovery, its scale of high-throughput experimental biology and platform-as-a-service model is structurally comparable.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Gordian Biotechnology social profiles
Digital presenceGordian Biotechnology financial estimates
Financial estimateRevenue estimate
Valuation estimate
Gordian Biotechnology leadership team
Management profileNumber of profiles
Profiles19 records
Gordian Biotechnology funding detail
Funding detailFunding overview
Funding rounds4 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Gordian Biotechnology M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Gordian Biotechnology
What does Gordian Biotechnology do?
Gordian Biotechnology operates a proprietary in vivo drug discovery platform that screens hundreds of therapeutic targets simultaneously in living animal models representative of human disease. The platform combines Patient Avatars (representative animal models, often naturally diseased), Mosaic Screening (pooled gene therapy delivery with barcoded cells), and Pythia (AI transcriptomics analysis) to identify drug targets for complex age-related diseases. Gordian monetizes this through non-exclusive research collaborations with large pharmaceutical companies (e.g., Pfizer for obesity) and internal development of its own therapeutic pipeline targeting osteoarthritis, MASH, HFpEF, pulmonary fibrosis, obesity, and chronic kidney disease.
Is Gordian Biotechnology a public or private company?
Gordian Biotechnology is a private company. It is classified as venture growth investor backed and is currently operating.
When was Gordian Biotechnology founded?
Gordian Biotechnology was founded in 2018. It employs 11 to 50 people.
Where is Gordian Biotechnology based?
Gordian Biotechnology is headquartered in South San Francisco, United States, in the North America region.
How does Gordian Biotechnology make money?
Two revenue lines are on record. Research Collaborations with Pharma is the primary driver. The others are internal Drug Development.
Who are Gordian Biotechnology's main competitors?
Direct peers on record are Recursion Pharmaceuticals, Insitro, Schrödinger, Valo Health and Isomorphic Labs. Emerging players are BPGbio and BioAge Labs. Ginkgo Bioworks is listed as a broad incumbent.
Does Gordian Biotechnology have an API?
No public API is recorded for Gordian Biotechnology.
What industry is Gordian Biotechnology in?
Gordian Biotechnology's product category is Drug Discovery Services. Its primary akta.pro industry code is HLAAAIAK, In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy), with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 8731.